No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹49.99Prev. Close
₹49.5Turnover(Lac.)
₹241.93Day's High
₹53.99Day's Low
₹47.2552 Week's High
₹61.852 Week's Low
₹26.69Book Value
₹17.55Face Value
₹10Mkt Cap (₹ Cr.)
74.56P/E
48.1EPS
1.08Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 13.97 | 6.53 | 6.53 | 6.53 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 11.46 | -5.31 | -5.43 | -5.3 |
Net Worth | 25.43 | 1.22 | 1.1 | 1.23 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -0.05 | -0.09 | -0.07 | -0.03 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | -0.23 | -0.31 | 0 | -0.06 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.09 | -2.52 | -0.16 | 0.01 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | -31.43 | 166.89 | 31.01 | 18.5 |
EBIT growth | -24.06 | 15,191.52 | -96.91 | 110.74 |
Net profit growth | -24.1 | 15,171.95 | -96.92 | 110.79 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,779.4 | 142.24 | 4,26,937.66 | 608.7 | 0.9 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 6,756.4 | 67.37 | 1,79,361.19 | 756 | 0.44 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,472.95 | 68.43 | 1,51,384.95 | 467 | 0.85 | 2,677 | 249.73 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,105.75 | 30.13 | 1,11,264.32 | 1,722 | 0.09 | 3,564.6 | 235.25 |
Cipla Ltd CIPLA | 1,376.75 | 32.31 | 1,11,220.1 | 384.64 | 0.94 | 3,840.92 | 423.36 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director & CFO
Chaitali Kalpataru Shah
Independent Non Exe. Director
Dinesh Chander Notiyal
Independent Non Exe. Director
Avani Savjibhai Godhaniya
Independent Non Exe. Director
Vivek Mukesh Yadav
Company Sec. & Compli. Officer
Tak Bhavana Tak
G2 & G3 Samarpan Complex,
chakala Andheri East,
Maharashtra - 400099
Tel: -
Website: http://www.bacilpharma.co.in
Email: bacilpha@yahoo.com
E-2/3 Ansa Indl Est,
Saki Vihar Road, Sakinaka Andheri(E),
Mumbai - 400072
Tel: 91-22-40430200/28470
Website: www.bigshareonline.com
Email: investor@bigshareonline.com
Summary
Incorporated as a private limited Company in Maharashtra in May, 1987, Bacil Pharma Limited (BPL) was converted into a Public limited company in October, 1988. The main business activity of the Compan...
Read More
Reports by Bacil Pharma Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.